Summary
Biogen Inc.'s 2016 10-K filing highlights a year of strategic shifts and product development advancements. The company completed the spin-off of its hemophilia business into an independent entity, Bioverativ Inc., effective February 1, 2017, allowing Biogen to focus more intently on its core neurological, rare, and autoimmune disease franchises. Financially, the company saw total revenues grow to $11.45 billion in 2016, an increase driven by strong performance in its multiple sclerosis (MS) products, particularly TECFIDERA, and the hemophilia segment (prior to the spin-off). The company also made significant progress in its pipeline, with key developments in spinal muscular atrophy (SMA) with the FDA approval of SPINRAZA, and advancements in its Alzheimer's disease candidate, aducanumab. However, Biogen also faced challenges, including a $1.25 billion settlement related to TECFIDERA intellectual property and ongoing competition in the MS market. The company's strategic focus on neurodegenerative diseases, rare diseases, and biosimilars, coupled with ongoing cost-saving initiatives, positions it for future growth while managing competitive and regulatory pressures.
Financial Highlights
55 data points| Revenue | $11.45B |
| Cost of Revenue | $1.48B |
| Gross Profit | $9.97B |
| SG&A Expenses | $1.95B |
| Operating Expenses | $6.30B |
| Operating Income | $5.15B |
| Interest Expense | $260.00M |
| Net Income | $3.70B |
| EPS (Basic) | $16.96 |
| EPS (Diluted) | $16.93 |
| Shares Outstanding (Basic) | 218.40M |
| Shares Outstanding (Diluted) | 218.80M |
Key Highlights
- 1Completion of the spin-off of the hemophilia business into Bioverativ Inc. (effective Feb 1, 2017), enabling greater focus on core therapeutic areas.
- 2Total revenues increased to $11.45 billion in 2016, driven by strong performance in Multiple Sclerosis (MS) products like TECFIDERA and the hemophilia segment (prior to spin-off).
- 3Significant pipeline progress with the FDA approval of SPINRAZA for Spinal Muscular Atrophy (SMA) in December 2016.
- 4Advancement of Alzheimer's disease candidate, aducanumab, with its acceptance into the EMA's PRIME program and FDA's Fast Track designation, and positive interim Phase 3 data.
- 5Introduction of biosimilars BENEPALI and FLIXABI in the EU market through the Samsung Bioepis joint venture.
- 6Incurrence of a $454.8 million charge in Q4 2016 related to the $1.25 billion settlement and license agreement with Forward Pharma concerning TECFIDERA intellectual property.
- 7Initiation of cost-saving measures and organizational realignment in anticipation of the Bioverativ spin-off and to enhance operational efficiency.